Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma

Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved objective response rates (ORR) with the use of the multi-kinase inhibitor lenvatinib. We...

Full description

Bibliographic Details
Main Authors: Laura Feeney, Yatin Jain, Matthew Beasley, Oliver Donnelly, Anthony Kong, Rafael Moleron, Chandran Nallathambi, Martin Rolles, Paul Sanghera, Aung Tin, Danny Ulahannan, Harriet S. Walter, Richard Webster, Robert Metcalf
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
adenoid cystic carcinoma
salivary gland cancer
lenvatinib
Online Access:https://www.mdpi.com/2072-6694/13/17/4336

Internet

https://www.mdpi.com/2072-6694/13/17/4336

Similar Items